Flavia Michelini

机构：AstraZeneca (Spain) · ORCID：0000-0002-3727-4887

发表论文 93 篇 · 总被引 2128 次 · h-index 15

代表论文

Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study (2024 · The Lancet Oncology · 被引 112)
EGFR-directed antibodies promote HER2 ADC internalization and efficacy (2024 · Cell Reports Medicine · 被引 34)
654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study (2023 · Annals of Oncology · 被引 25)
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study. (2024 · Journal of Clinical Oncology · 被引 11)
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02). (2024 · Journal of Clinical Oncology · 被引 6)
Efficacy and safety of trastuzumab deruxtecan among patients with HER2-expressing solid tumors: Biomarker and subgroup analyses from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study (2024 · Gynecologic Oncology · 被引 4)